Back to Stocks

AXSM

Axsome Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologyMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Axsome Therapeutics has successfully transitioned from a clinical-stage entity to a commercial powerhouse, reporting a 57% year-over-year revenue increase to $191.2 million in the first quarter of 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline revenue growth, Axsome's financial health reveals significant vulnerabilities.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every AXSM filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a classic biotech trade-off: impressive top-line commercial acceleration versus precarious operational leverage. Axsome has proven it can sell its products and win regulatory approvals, but it has yet to prove it can do so without burning through its cash reserves. The shift in the investment narrative now centers on whether the Alzheimer's agitation label for AUVELITY can provide the necessary scale to offset the massive SG&A spend and debt obligations. Investors must weigh the ability of the company to maintain its patent shields against the reality of its debt structure and insider behavior. While the revenue trajectory is undeniably bullish, the underlying financial architecture is fragile, making the company highly sensitive to any miss in sales targets or an adverse legal ruling. The path to cash flow positivity is clear, but the margin for error is dangerously slim.

Selected Quarter

Core Takeaway

Axsome is successfully scaling its product portfolio, but high operational burn and strict debt covenants create a high-risk, high-reward scenario.

Investor Lens

The trade-off is between the explosive potential of new product labels and the risk of a liquidity crisis or generic erosion.

Watch Next

Quarterly cash burn trends and the outcome of the Apotex Paragraph IV litigation for SYMBRAVO.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.28Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat
90%
bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression
60%
bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action
80%
neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure
50%
bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat
90%
bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression
60%
bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action
80%
neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure
50%
bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat
90%
bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression
60%
bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action
80%
neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure
50%
bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat
90%
bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression
60%
bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action
80%
neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure
50%
bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat
90%
bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression
60%
bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action
80%
neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure
50%
bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat
90%
bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression
60%
bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action
80%
neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure
50%
bullishMay 4

Revenue surged 57% year-over-year to $191.2 million.

earnings beat
90%
bearishMay 4

SG&A expenses grew 53% to $185 million, nearly matching revenue growth.

margin compression
60%
bullishMay 4

FDA approved AUVELITY for Alzheimer's disease agitation in April 2026.

regulatory action
80%
neutralMay 4

Refinanced debt via Blackstone with a $30M minimum liquidity covenant.

debt restructure
50%

Filing History

10-QMay 4, 2026
Expand Sequence

The Q1 2026 filing presents a classic biotech trade-off: impressive top-line commercial acceleration versus precarious operational leverage. Axsome has proven it can sell its products and win regulatory approvals, but it has yet to prove it can do so without burning through its cash reserves. The shift in the investment narrative now centers on whether the Alzheimer's agitation label for AUVELITY can provide the necessary scale to offset the massive SG&A spend and debt obligations. Investors must weigh the ability of the company to maintain its patent shields against the reality of its debt structure and insider behavior. While the revenue trajectory is undeniably bullish, the underlying financial architecture is fragile, making the company highly sensitive to any miss in sales targets or an adverse legal ruling. The path to cash flow positivity is clear, but the margin for error is dangerously slim.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.